WASHINGTON, March 29 (Reuters) - The U.S. Food and Drug Administration has called for an outside review of Abbott Laboratories Inc.'s (ABT.N: Quote, Profile , Research) diagnostics unit in Texas, citing continuing quality control problems, according to a warning letter released on Thursday.
